{"id":1655,"date":"2021-08-02T04:11:16","date_gmt":"2021-08-02T04:11:16","guid":{"rendered":"https:\/\/emergencydrug.com\/?post_type=product&p=1655"},"modified":"2024-10-01T08:21:49","modified_gmt":"2024-10-01T08:21:49","slug":"sunitix-sunitinib-25-mg","status":"publish","type":"product","link":"https:\/\/emergencydrug.com\/ar\/shop\/sunitix-sunitinib-25-mg\/","title":{"rendered":"Sunitix (Sunitinib) 25 MG \u2013 28 Capsules"},"content":{"rendered":"

Product Features:<\/em><\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n\n
Product Name<\/td>\n: Sunitix<\/td>\n<\/tr>\n
Generic Name<\/td>\n: Sunitinib<\/td>\n<\/tr>\n
Manufacturer<\/td>\n: Beacon Pharma Ltd<\/td>\n<\/tr>\n
Indication<\/td>\n: Kidney cancer<\/td>\n<\/tr>\n
Formulation<\/td>\n: Capsule<\/td>\n<\/tr>\n
Strength<\/td>\n: 25 mg<\/td>\n<\/tr>\n
Quantity<\/td>\n: 28 Capsules<\/td>\n<\/tr>\n
Storage<\/td>\n: Below 30\u00b0<\/td>\n<\/tr>\n
Registrations<\/td>\n: Export Only<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n

Sunitix 25 mg (Sunitinib) Tablets is an anti-cancer medication. It blocks the action of the abnormal protein that signals cancer cells to multiply. This prevent to stop or slow the spread of cancer cells<\/a>.<\/p>\n

\n

Indications Sunitix <\/strong><\/h4>\n<\/div>\n
\n

Gastrointestinal Stromal Tumor (GIST): It indicate for the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate<\/a>.<\/p>\n

Advanced Renal Cell Carcinoma (RCC): This indicate for the treatment of advanced renal cell carcinoma<\/a>.<\/p>\n

Advanced Pancreatic Neuroendocrine Tumors (pNET): Sunitix indicate for the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors in patients with unresectable locally advanced or metastatic disease<\/a>.<\/p>\n

\n

Pharmacology<\/h4>\n<\/div>\n
\n

Sunitix 25 mg (Sunitinib) inhibits cellular signaling by targeting multiple receptor tyrosine kinases (RTKs)<\/a>.<\/p>\n

These include all receptors for platelet-derived growth factor (PDGF-Rs) and vascular endothelial growth factor receptors (VEGFRs). which play a role in both tumor angiogenesis and tumor cell proliferation. The simultaneous inhibition of these targets. Therefore reduces tumor vascularization and triggers cancer cell apoptosis<\/a> and thus results in tumor shrinkage.<\/p>\n

Sunitinib also inhibits CD117 (c-KIT), the receptor tyrosine kinase that (when improperly activated by mutation) drives the majority of gastrointestinal stromal cell tumors. It has been recommended as a second-line therapy for patients whose tumors develop mutations in c-KIT that make them resistant to imatinib, or who the cannot tolerate the drug.<\/p>\n

In addition, Sunitinib binds other receptors. These include: RET, CD114, CD135. The fact that Sunitix targets many different receptors. Leads to many of its side effects such as the classic hand-foot syndrome, stomatitis, and other dermatologic toxicities.<\/p>\n

\n

Dosage & Administration<\/h4>\n<\/div>\n
\n

Recommended Dose For GIST And RCC: The recommended dose of medicine for gastrointestinal stromal tumor (GIST) and advanced renal cell carcinoma (RCC) is one 50 mg oral dose need to take once daily. On a schedule of 4 weeks on treatment follow by 2 week<\/a>s off (Schedule 4\/2). Sunitix (Sunitinib) take to with or without food.<\/p>\n

Recommended Dose For pNET: The recommended dose of Capsule \u00a0for pancreatic neuroendocrine tumors (pNET)<\/a> is 37.5 mg taken orally once daily continuously without a scheduled off-treatment period.<\/p>\n

Dose Modification: Dose interruption and\/or dose modification in 12.5 mg increments or decrements recommend based on individual safety and tolerability. The maximum dose administered in the Phase 3 pNET study was 50 mg daily.<\/p>\n

Alternate concomitant medication with no or minimal enzyme inhibition potential is recommended. A dose reduction to a minimum of 37.5 mg (GIST and RCC) or 25 mg (pNET). Daily consider as Sunitix must co-administer with a strong CYP3A4 inhibitor<\/p>\n

Selection of an alternate concomitant medication with no or minimal enzyme induction potential recommend. A dose increase for Sunitix\u00a0 to a maximum of 87.5 mg (GIST and RCC) or 62.5 mg (pNET) daily consider if Sunitix must co-administer with a CYP3A4 inducer. If dose increase, the patient monitor carefully for toxicity.<\/p>\n

\n

Interaction<\/h4>\n<\/div>\n
\n

Increased plasma cone with strong CYP3A4 inhibitors (eg ketoconazole, ritonavir, itraconazole, erythromycin, clarithromycin, grapefruit juice). Decreased plasma cone with strong CYP3A4 inducers [eg rifampin, dexamethasone, phenytoin, carbamazepine, phenobarb, St. John’s wort (Hypericum perforatum)]. Anticoagulants eg warfarin, acenocoumarol (periodically monitor platelets, prothrombin time\/INR & physical exam).<\/p>\n

\n
\n

Side Effects<\/h4>\n<\/div>\n
\n

Common side effects of Sunitix (Sunitinib) include:<\/p>\n